Skip to main content
Premium Trial:

Request an Annual Quote

AltheaDx Teams with Institute on Pediatric Cancer MDx

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – AltheaDx today said that it will collaborate with the Nicholas Conor Institute for Pediatric Cancer Research on developing molecular diagnostic tests for pediatric cancer.

The San Diego-based firm, which is developing microarray-based genetic tests, said that the collaboration will upon its existing test for diagnosis of multiple pediatric tumor types, and expand the test beyond diagnosis to prognosis and therapeutic monitoring. It said that the goal of the alliance is to create a single genetic panel from a single biopsy that will diagnose and inform treatment.

The Nicholas Conor Institute is a San Diego-based non-profit focused on finding new diagnostics and treatments for pediatric cancer.

The partners noted that they are currently seeking funding to cover the development costs of the program.

As reported last week by GenomeWeb Daily News, AltheaDx recently raised $6 million in a Series A round of equity financing.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.